CORCEPT THERAPEUTICS INC (CORT)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$110.0M
Cash & Equivalents
$16.8M
Quarterly Burn Rate
20 mo
Est. Cash Runway
$9,863M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
MIFEPRISTONE
KORLYM |
APPROVED | Adenocarcinoma, Adrenocortical Carcinoma, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Antipsychotic-induced Weight Gain, Antipsychotic-induced Weight Gain (AIWG), Breast Cancer, Carcinoma, Pancreatic Ductal, Carcinoma, Transitional Cell, Central Adrenal Insufficiency, Childhood Trauma, Cushing Syndrome, Cushing's Disease, Cushing's Syndrome, Depressive Disorder, Major, Diabetes Mellitus, Type 2, Drug Interaction Potentiation, Endometrial Cancer, Fallopian Tube Cancer, Fallopian Tube Neoplasms, Food-drug Interaction, Healthy, Healthy Adults, Healthy Subjects, Hepatic Impairment, Hypercortisolism, Major Depressive Disorder, Metabolic Dysfunction-associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Mifepristone, Neoplas |
|
RELACORILANT
LIFYORLI (COPACKAGED) |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-09-01 | Phase2 Readout | — |
| 2026-09-01 | Phase2 Readout | — |
| 2026-09-15 | Phase2 Readout | — |
| 2026-10-01 | Phase2 Readout | — |
| 2026-10-30 | Phase1 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (11)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary ... | PHASE3 | Active Not Recruiting | 381 |
| NCT06099769 | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast... | PHASE2 | Recruiting | 201 |
| NCT07259317 | Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | PHASE2 | Recruiting | 80 |
| NCT07276373 | Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | PHASE2 | Recruiting | 50 |
| NCT06108219 | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Asso... | PHASE2 | Active Not Recruiting | 175 |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | PHASE2 | Recruiting | 270 |
| NCT05407324 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | Recruiting | 279 |
| NCT03604198 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | PHASE2 | Active Not Recruiting | 125 |
| NCT06689254 | REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonis... | PHASE2 | Recruiting | 60 |
| NCT06947304 | Evaluation of Miricorilant on Liver Fat in Patients With MASLD | PHASE1 | Recruiting | 8 |
| NCT07553663 | Evaluating the Pharmacokinetics and Safety of Miricorilant | PHASE1 | Recruiting | 15 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-17 | 8-K | CORCEPT THERAPEUTICS INC (CORT) (CIK 0001088856) - EX-99.1 | EDGAR |